PT2589602T - Desenvolvimento de componentes de vacina contra o vírus da dengue - Google Patents

Desenvolvimento de componentes de vacina contra o vírus da dengue

Info

Publication number
PT2589602T
PT2589602T PT121823199T PT12182319T PT2589602T PT 2589602 T PT2589602 T PT 2589602T PT 121823199 T PT121823199 T PT 121823199T PT 12182319 T PT12182319 T PT 12182319T PT 2589602 T PT2589602 T PT 2589602T
Authority
PT
Portugal
Prior art keywords
development
dengue virus
virus vaccine
vaccine components
components
Prior art date
Application number
PT121823199T
Other languages
English (en)
Inventor
R Murphy Brian
S Whitehead Stephen
e blaney Joseph
Ching-Juh Lai
Original Assignee
The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of filed Critical The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of
Publication of PT2589602T publication Critical patent/PT2589602T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT121823199T 2006-08-15 2007-08-15 Desenvolvimento de componentes de vacina contra o vírus da dengue PT2589602T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83772306P 2006-08-15 2006-08-15

Publications (1)

Publication Number Publication Date
PT2589602T true PT2589602T (pt) 2016-07-13

Family

ID=39083099

Family Applications (1)

Application Number Title Priority Date Filing Date
PT121823199T PT2589602T (pt) 2006-08-15 2007-08-15 Desenvolvimento de componentes de vacina contra o vírus da dengue

Country Status (15)

Country Link
US (8) US8337860B2 (pt)
EP (2) EP2054428B9 (pt)
CN (2) CN103602689B (pt)
AU (1) AU2007285929B2 (pt)
BR (2) BRPI0716455A8 (pt)
CA (2) CA3004991C (pt)
CY (1) CY1118003T1 (pt)
DK (2) DK2054428T3 (pt)
ES (1) ES2585553T3 (pt)
HU (1) HUE029333T2 (pt)
LT (1) LT2589602T (pt)
PL (1) PL2589602T3 (pt)
PT (1) PT2589602T (pt)
SI (1) SI2589602T1 (pt)
WO (1) WO2008022196A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2339011T3 (en) * 2002-01-10 2015-07-06 Us Government Chimeric of West Nile virus and dengue-4 virus for use in a live virus vaccine for the prevention of disease caused by the West Nile Virus
SI1554301T1 (sl) 2002-05-03 2011-01-31 Us Health VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE
US8337860B2 (en) * 2006-08-15 2012-12-25 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Development of dengue virus vaccine components
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN107913406A (zh) * 2009-06-01 2018-04-17 武田疫苗公司 施用针对登革病毒的疫苗的组合物和方法
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
EP2931310A4 (en) 2012-12-14 2016-05-25 Takeda Vaccines Inc COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
SG11201507460PA (en) * 2013-03-15 2015-10-29 Takeda Vaccines Inc Compositions and methods for dengue virus chimeric constructs in vaccines
MY187896A (en) 2013-06-21 2021-10-27 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
MY179251A (en) * 2014-11-02 2020-11-02 Univ North Carolina Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
CN106999568A (zh) * 2014-12-22 2017-08-01 默沙东公司 登革病毒疫苗组合物及其使用方法
EP3316897A4 (en) 2015-07-02 2019-03-13 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
EP3353287B1 (en) 2015-09-26 2022-03-09 Primevax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
US11123420B2 (en) * 2015-09-30 2021-09-21 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
KR20180127397A (ko) 2016-03-11 2018-11-28 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 생약독화된 지카 바이러스 백신
WO2018093907A1 (en) * 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
WO2018129202A1 (en) * 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
US11730801B2 (en) * 2017-02-14 2023-08-22 Board Of Regents, The University Of Texas System Live attenuated Zika virus with 3'UTR deletion, vaccine containing and use thereof
US10240130B2 (en) 2017-02-15 2019-03-26 The Board Of Regents Of The University Of Texas System CDNA clone-launched platform for high-yield production of inactivated zika virus
CN117752780A (zh) 2017-12-07 2024-03-26 默沙东有限责任公司 登革病毒疫苗组合物的制剂
BR112022001476A2 (pt) 2019-08-16 2023-10-03 Takeda Vaccines Inc Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit
WO2022182835A1 (en) * 2021-02-26 2022-09-01 Duke University Compositions for and methods of improving gene therapy
WO2023161715A1 (en) * 2022-02-22 2023-08-31 Futr Bio Ltda. Next generation mrna vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
SI1554301T1 (sl) * 2002-05-03 2011-01-31 Us Health VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE
EP1761277A1 (en) * 2004-06-14 2007-03-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES West nile viruses with mutations in the 3' terminal stem and loop secondary structure for use as live virus vaccines
US8337860B2 (en) * 2006-08-15 2012-12-25 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Development of dengue virus vaccine components

Also Published As

Publication number Publication date
US20130089567A1 (en) 2013-04-11
US20100104598A1 (en) 2010-04-29
US11332722B2 (en) 2022-05-17
BR122020023372B1 (pt) 2021-11-30
HUE029333T2 (en) 2017-03-28
US10160957B2 (en) 2018-12-25
WO2008022196A3 (en) 2009-03-12
CA3004991C (en) 2022-08-30
US20240084269A1 (en) 2024-03-14
DK2589602T3 (en) 2016-07-25
US20200318083A1 (en) 2020-10-08
CN101657463B (zh) 2013-09-18
WO2008022196A2 (en) 2008-02-21
US9090873B2 (en) 2015-07-28
US11746335B2 (en) 2023-09-05
EP2589602A3 (en) 2013-10-09
LT2589602T (lt) 2016-10-10
CN101657463A (zh) 2010-02-24
US20180171308A1 (en) 2018-06-21
DK2054428T3 (da) 2013-08-26
PL2589602T3 (pl) 2016-11-30
AU2007285929A2 (en) 2009-04-23
CA2661296C (en) 2018-06-26
US20190119654A1 (en) 2019-04-25
BRPI0716455A8 (pt) 2019-01-15
ES2585553T3 (es) 2016-10-06
EP2054428B9 (en) 2013-11-13
SI2589602T1 (sl) 2016-08-31
BRPI0716455A2 (pt) 2014-03-04
CN103602689B (zh) 2016-08-24
CA3004991A1 (en) 2008-02-21
US10724007B2 (en) 2020-07-28
EP2054428B1 (en) 2013-06-05
AU2007285929B2 (en) 2013-09-05
CY1118003T1 (el) 2017-05-17
EP2589602B1 (en) 2016-04-06
USRE46042E1 (en) 2016-06-28
US20220251521A1 (en) 2022-08-11
AU2007285929A1 (en) 2008-02-21
EP2054428A2 (en) 2009-05-06
EP2589602A2 (en) 2013-05-08
CN103602689A (zh) 2014-02-26
US8337860B2 (en) 2012-12-25
CA2661296A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
LT2589602T (lt) Dengė viruso vakcinos komponentų gavimas
NO2021010I1 (no) telostritat ethyl
HRP20160410T8 (hr) Inhibitori hepatitis c virusa
IL198087A0 (en) Methods of inactivating viruses
ZA201004688B (en) Novel vaccines against multiple subtypes of dengue virus
DE602007003596D1 (de) Impfstoff
IL196024A0 (en) Influenza vaccine
IL189329A0 (en) Vaccination against dengue virus infection
CR10571A (es) Vacuna virica recombinante
DE602007003533D1 (de) Karosserierahmenbauteil
BRPI0718548A2 (pt) Estabilização de vacinas por liofilização
SI2422810T1 (sl) Influenčno cepivo
ZA200809056B (en) Influenza virus vaccine
EP2054081A4 (en) VACCINE AGAINST THE JC VIRUS
ZA200802176B (en) Vaccination against dengue virus infection
ZA200900062B (en) Influenza vaccine
HUS1500008I1 (hu) Hepatitis C vírus inhibitorok
GB0623218D0 (en) Influenza vaccine
GB0618195D0 (en) Influenza vaccine
GB0623865D0 (en) Influenza vaccine
GB0625453D0 (en) Influenza vaccine
GB0619090D0 (en) Influenza vaccine
CN300798843S (zh) 手持搅拌器(ha-3062)
GB0605333D0 (en) Treatment of influenza